Cellsource Co Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Metrics to compare | 4880 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4880PeersSector | |
|---|---|---|---|---|
P/E Ratio | 75.8x | 12.8x | −0.5x | |
PEG Ratio | - | −0.29 | 0.00 | |
Price/Book | 1.1x | 1.6x | 2.6x | |
Price / LTM Sales | 1.8x | 1.8x | 3.0x | |
Upside (Analyst Target) | 158.8% | 41.1% | 58.6% | |
Fair Value Upside | Unlock | 7.8% | 10.2% | Unlock |
CellSource Co., Ltd. engages in the regenerative medicine-related businesses in Japan. The company provides processing services to extract adipose-derived stem cells from patients’ adipose tissues, and to prepare platelet-rich plasma from patients’ blood; and offers support services for medical facilities providing regenerative medicine therapy. It is also involved in the sale of human stem cell-derived cosmetic ingredients; and Signalift series of anti-aging products, including a serum. The company was incorporated in 2015 and is headquartered in Shibuya, Japan.